1. Peterson JL, DiClemente RJ. Handbook of HIV prevention. Kluwer Academic/Plenum; 2000.
4. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS 2010;24 Suppl 4:S70-S80.
5. Cohen MS, Dallabetta G, Laga M, Holmes KK. A new deal in HIV prevention: lessons from the global approach. Ann Intern Med 1994;120:340-341.
6. Silverman BG, Gross TP. Use and effectiveness of condoms during anal intercourse: a review. Sex Transm Dis 1997;24:11-17.
8. Fontanet AL, Saba J, Chandelying V, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 1998;12:1851-1859.
11. Weidner W. Words of wisdom. Re: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial, and Re: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Eur Urol 2007;52:605-606.
12. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
13. Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Ann Med 2017;49:534-544.
14. Ng BE, Butler LM, Horvath T, Rutherford GW. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev 2011;(3):CD001220.
15. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999;353:525-535.
16. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
17. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
19. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-434.
24. Gossop M, Marsden J, Stewart D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care 2002;14:77-93.
25. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.
26. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003;289:959-962.
27. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180.
29. Centers for Disease Control (CDC). Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985;34:721-726. 731-732.
30. Global programme on AIDS. Consensus statement from the WHO/UNICEF consultation on HIV transmission and breast-feeding. Wkly Epidemiol Rec 1992;67:177-179.
31. Centers for Disease Control (CDC). Recommendations for prevention of HIV transmission in health-care settings. MMWR Suppl 1987;36:1S-18S.
32. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR Recomm Rep 1990;39((RR-1):1-14.
33. Kuhar DT, Henderson DK, Struble KA, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. Accessed November 24, 2023.
https://stacks.cdc.gov/view/cdc/20711